PE20030935A1 - Formulacion de atorvastatina estabilizada con aditamentos de metales alcalinos - Google Patents
Formulacion de atorvastatina estabilizada con aditamentos de metales alcalinosInfo
- Publication number
- PE20030935A1 PE20030935A1 PE2003000161A PE2003000161A PE20030935A1 PE 20030935 A1 PE20030935 A1 PE 20030935A1 PE 2003000161 A PE2003000161 A PE 2003000161A PE 2003000161 A PE2003000161 A PE 2003000161A PE 20030935 A1 PE20030935 A1 PE 20030935A1
- Authority
- PE
- Peru
- Prior art keywords
- atorvastatin
- crusher
- alkaline metal
- refers
- less
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title abstract 6
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title abstract 6
- 229960005370 atorvastatin Drugs 0.000 title abstract 6
- 239000000654 additive Substances 0.000 title abstract 2
- 229910052751 metal Inorganic materials 0.000 title abstract 2
- 239000002184 metal Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000002245 particle Substances 0.000 abstract 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- 239000004115 Sodium Silicate Substances 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 229910052782 aluminium Inorganic materials 0.000 abstract 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 abstract 1
- 229910052911 sodium silicate Inorganic materials 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 239000012749 thinning agent Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A FORMULAS FARMACEUTICAS ESTABILIZADAS DE 1% Y 50% DE ATORVASTATINA AMORFA Y/O CRISTALINA QUE COMPRENDE ATORVASTATINA (DE CALCIO, MAGNESIO, ALUMINIO, HIERRO, ZINC) CON UN TAMANO DE PARTICULAS (d90) MENOR DE 150µm; QUE SE CARACTERIZA PORQUE LOS INTERVALOS DE CONFIANZA DEL 90% DE LOS VALORES CORRESPONDIENTES AL AREA QUE CABE BAJO LA CURVA DE CONCENTRACION EN EL TIEMPO DE ATORVASTATINA AUC (0-t) Y LA MAXIMA CONCENTRACION DE PLASMA (CMAX) FLUCTUAN ENTRE 0.80 Y 1.25; EXCIPIENTES SELECCIONADOS ENTRE AGENTES DILUYENTES, SURFACTANTES, ANTIOXIDANTES, DESINTEGRANTES, AGLUTINANTES, LUBRICANTES, DESLIZANTES, QUELANTES; DE 1.2% A NO MENOS DE 5% DE UN ADITIVO COMO SAL DE METAL ALCALINO TAL COMO CARBONATO; BICARBONATO, HIDROXIDO, SILICATO DE SODIO. TAMBIEN SE REFIERE A UN METODO PARA PREPARAR QUE COMPRENDE REDUCIR EL TAMANO DE LAS PARTICULAS DE ATORVASTATINA AMORFA MEDIANTE EL EMPLEO DE UN TRITURADOR CON CHORRO DE AIRE, QUEBRADORA DE BOLAS, TRITURADORA, PULVERIZADOR; FORMAR UNA MEZCLA AL COMBINAR ATORVASTATINA AMORFA CON PARTICULAS DE TAMANO REDUCIDO, CON EXCIPIENTES; COMPRENSION DE LA MEZCLA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN112DE2002 | 2002-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030935A1 true PE20030935A1 (es) | 2003-10-30 |
Family
ID=27620520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000161A PE20030935A1 (es) | 2002-02-14 | 2003-02-14 | Formulacion de atorvastatina estabilizada con aditamentos de metales alcalinos |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20030175338A1 (es) |
| EP (1) | EP1336405A1 (es) |
| JP (1) | JP2005522444A (es) |
| KR (1) | KR20040101229A (es) |
| CN (1) | CN1642526A (es) |
| AP (1) | AP2004003112A0 (es) |
| AR (1) | AR038839A1 (es) |
| AU (1) | AU2003245736A1 (es) |
| BR (1) | BR0307720A (es) |
| CA (1) | CA2475722A1 (es) |
| CO (1) | CO5600997A2 (es) |
| EA (1) | EA200401059A1 (es) |
| EC (1) | ECSP045235A (es) |
| HR (1) | HRP20040829A2 (es) |
| IL (1) | IL163550A0 (es) |
| IS (1) | IS7404A (es) |
| MX (1) | MXPA04007905A (es) |
| NO (1) | NO20043790L (es) |
| OA (1) | OA12777A (es) |
| PE (1) | PE20030935A1 (es) |
| PL (1) | PL371337A1 (es) |
| WO (1) | WO2003068191A1 (es) |
| ZA (1) | ZA200406970B (es) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| US7361772B2 (en) * | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
| CZ2004943A3 (cs) | 2002-03-18 | 2005-02-16 | Biocon Limited | Amorfní HMG-CoA inhibitory obsahující reduktázu s požadovanou velikostí částic |
| US7179942B2 (en) | 2002-07-05 | 2007-02-20 | Bicon Limited | Halo-substituted active methylene compounds |
| US7232920B2 (en) | 2003-04-22 | 2007-06-19 | Biocon | Process for stereoselective reduction of β-ketoesters |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| ES2298763T3 (es) * | 2003-08-05 | 2008-05-16 | Zentiva, A.S. | Metodos para la estabilizacion de la atorvastatina. |
| US7557238B2 (en) | 2003-09-18 | 2009-07-07 | Biocon Limited | Process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate |
| WO2005053656A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride |
| DE102004008074A1 (de) | 2004-02-19 | 2005-09-15 | Heidelberger Druckmaschinen Ag | Verfahren und Testform zum Abgleichen der Belichtungsköpfe in einem Belichter für Druckvorlagen |
| MX2007001553A (es) * | 2004-08-06 | 2008-03-07 | Transform Pharmaceuticals Inc | Nuevas composiciones farmaceuticas de estatina y metodos de tratamiento relacionados. |
| US20090042979A1 (en) * | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
| SG155189A1 (en) * | 2004-08-06 | 2009-09-30 | Transform Pharmaceuticals Inc | Novel fenofibrate formulations and related methods of treatment |
| WO2006039441A2 (en) | 2004-09-30 | 2006-04-13 | Dr. Reddy's Laboratories Ltd. | Amorphous atorvastatin calcium |
| WO2006046109A1 (en) * | 2004-10-28 | 2006-05-04 | Warner-Lambert Company Llc | Process for forming amorphous atorvastatin |
| AU2005305460B2 (en) * | 2004-11-22 | 2011-04-21 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| US20090088465A1 (en) * | 2004-12-02 | 2009-04-02 | Stephen Craig Dyar | Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same |
| ES2263370B1 (es) * | 2005-02-16 | 2007-12-01 | Ercros Industrial, S.A. | Atorvastatina calcica amorfa estabilizada y procedimiento para su obtencion. |
| WO2006123358A2 (en) * | 2005-02-22 | 2006-11-23 | Sun Pharmaceutical Industries Limited | Stabilized atorvastatin-containing formulation |
| WO2006117761A2 (en) * | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Magnesium salts of hmg-coa reductase inhibitors |
| US20070004671A1 (en) * | 2005-05-20 | 2007-01-04 | Agarwal Sudeep K | Stable desloratadine compositions |
| AU2006264407B2 (en) * | 2005-07-04 | 2012-08-30 | Ramu Krishnan | Improved drug or pharmaceutical compounds and a preparation thereof |
| JP2009515816A (ja) * | 2005-08-04 | 2009-04-16 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法 |
| CA2628716C (en) * | 2005-11-10 | 2016-09-27 | Alphapharm Pty Ltd | Process to control particle size |
| AU2006313009B2 (en) * | 2005-11-10 | 2013-10-24 | Alphapharm Pty Ltd | Process to control particle size |
| DK1957452T3 (da) | 2005-11-21 | 2010-07-26 | Warner Lambert Co | Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium |
| US20090111997A1 (en) * | 2005-11-23 | 2009-04-30 | Aaron Cote | Method of Generating Amorphous Solid for Water-Insoluble Pharmaceuticals |
| US20100168201A1 (en) * | 2005-11-29 | 2010-07-01 | Biocan Limited | Polymorphs of [R-(R*, R*) ]-2-(4-Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid Magnesium Salt (2:1) |
| EP1810667A1 (en) * | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| US20070202159A1 (en) * | 2006-02-02 | 2007-08-30 | Mathur Rajeev S | Pharmaceutical composition comprising stabilized statin particles |
| EP1818049A3 (en) * | 2006-02-10 | 2008-11-19 | LifeCycle Pharma A/S | Stabilized Atorvastatin |
| WO2007099552A2 (en) * | 2006-03-02 | 2007-09-07 | Matrix Labaratories Ltd | Novel crystalline form of atovastatin hemi-magnesium |
| HU227696B1 (en) * | 2006-04-13 | 2011-12-28 | Egyt Gyogyszervegyeszeti Gyar | Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it |
| SI22255A (sl) * | 2006-04-14 | 2007-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah |
| WO2007132472A1 (en) * | 2006-05-11 | 2007-11-22 | Biocon Limited | A crystalline form b4 of atorvastatin magnesium and a process thereof |
| US20080038332A1 (en) * | 2006-08-10 | 2008-02-14 | Cai Gu Huang | Stable pharmaceutical formulation comprising atorvastatin calcium |
| HU227610B1 (en) * | 2006-09-18 | 2011-09-28 | Richter Gedeon Nyrt | Pharmaceutical compositions containing rosuvastatin potassium |
| AU2007300071A1 (en) * | 2006-09-27 | 2008-04-03 | Dr. Reddy's Laboratories Ltd. | Atorvastatin pharmaceutical compositions |
| CA2673418A1 (en) | 2006-12-21 | 2008-06-26 | Alphapharm Pty Ltd | Pharmaceutical compound and composition |
| IS8587A (is) * | 2006-12-27 | 2008-06-28 | Actavis Group Hf. | Atorvastatin lyfjasamsetning |
| CN101224205B (zh) * | 2007-01-20 | 2010-11-17 | 石药集团中奇制药技术（石家庄）有限公司 | 一种阿托伐他汀和左旋氨氯地平的组合物及其制备方法 |
| IS8607A (is) * | 2007-02-09 | 2008-08-10 | Actavis Group Hf. | Stöðugar atorvastatin samsetningar |
| CZ300047B6 (cs) * | 2007-03-02 | 2009-01-21 | Zentiva, A. S. | Farmaceutická kompozice s obsahem úcinné látky atorvastatinu |
| US20100152274A1 (en) * | 2007-04-13 | 2010-06-17 | Nicox S.A. | Crystalline forms of atorvastatin 4-(nitrooxy) butyl ester |
| WO2009013633A2 (en) * | 2007-07-20 | 2009-01-29 | Actavis Group Ptc Ehf | Amorphous coprecipitates of atorvastatin pharmaceutically acceptable salts |
| WO2009024889A2 (en) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
| US20110064816A1 (en) * | 2008-05-13 | 2011-03-17 | Dr. Reddy's Laboratories Ltd. | Atorvastatin compositions |
| CN102014876B (zh) * | 2008-05-15 | 2013-03-27 | 弗门尼舍有限公司 | 活性成分递送系统 |
| EP2127628A1 (en) | 2008-05-27 | 2009-12-02 | Ranbaxy Laboratories Limited | Unit dose pack |
| CN102105427A (zh) * | 2008-07-25 | 2011-06-22 | 阿尔法制药有限公司 | 粒度直径范围(D90)为大于3μm至约10μm的阿托伐醌 |
| WO2010036600A1 (en) * | 2008-09-24 | 2010-04-01 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of atorvastatin |
| US20100151034A1 (en) * | 2008-09-30 | 2010-06-17 | Astellas Pharma Inc. | Granular pharmaceutical composition of atorvastatin for oral administration |
| CN101791297B (zh) * | 2010-02-10 | 2012-03-28 | 中国药科大学 | 阿托伐他汀钙口崩片及其制备方法 |
| WO2011121823A1 (ja) * | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | 経口投与用粒子状医薬組成物 |
| WO2011121824A1 (ja) * | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | 口腔内崩壊錠 |
| US8372877B2 (en) | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
| WO2011139256A2 (en) * | 2010-05-04 | 2011-11-10 | Bilgic Mahmut | Stable rosuvastatin formulations |
| HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
| WO2011154009A1 (en) * | 2010-06-10 | 2011-12-15 | Lifecycle Pharma A/S | Composition comprising an active principle in an amorphous form and a porous adsorbent material |
| US20120165386A1 (en) * | 2010-12-27 | 2012-06-28 | Ranbaxy Laboratories Limited | Stable oral pharmaceutial composition of atorvastatin |
| WO2013072770A2 (en) | 2011-11-15 | 2013-05-23 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising atorvastatin and glimepiride |
| CN104069502B (zh) * | 2013-03-29 | 2018-02-16 | 北京罗诺强施医药技术研发中心有限公司 | 复合骨架材料及其药物组合物 |
| JP6507808B2 (ja) * | 2015-04-09 | 2019-05-08 | ニプロ株式会社 | 口腔内崩壊錠 |
| WO2017106130A1 (en) | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Process for preparing pharmaceutical compositions |
| EP3184103A1 (en) | 2015-12-21 | 2017-06-28 | Hexal AG | Pharmaceutical composition comprising atorvastatin or a salt thereof |
| CN106420645A (zh) * | 2016-11-24 | 2017-02-22 | 浙江新东港药业股份有限公司 | 一种含阿托伐他汀钙片及制备方法 |
| CN108421045B (zh) * | 2018-04-02 | 2021-09-24 | 北京海晶生物医药科技有限公司 | 一种阿托伐他汀钙组合物、制剂及其制备方法 |
| CN109044989A (zh) * | 2018-10-09 | 2018-12-21 | 河南师范大学 | 一种阿托伐他汀钙胶囊制剂及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| DE69324504T2 (de) * | 1993-01-19 | 1999-08-26 | Warner-Lambert Co. | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
| SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
-
2003
- 2003-02-14 OA OA1200400219A patent/OA12777A/en unknown
- 2003-02-14 CN CNA038070286A patent/CN1642526A/zh active Pending
- 2003-02-14 AR ARP030100494A patent/AR038839A1/es not_active Application Discontinuation
- 2003-02-14 US US10/367,552 patent/US20030175338A1/en not_active Abandoned
- 2003-02-14 MX MXPA04007905A patent/MXPA04007905A/es not_active Application Discontinuation
- 2003-02-14 AU AU2003245736A patent/AU2003245736A1/en not_active Abandoned
- 2003-02-14 PE PE2003000161A patent/PE20030935A1/es not_active Application Discontinuation
- 2003-02-14 KR KR10-2004-7012657A patent/KR20040101229A/ko not_active Withdrawn
- 2003-02-14 HR HR20040829A patent/HRP20040829A2/xx not_active Application Discontinuation
- 2003-02-14 BR BR0307720-9A patent/BR0307720A/pt not_active IP Right Cessation
- 2003-02-14 IL IL16355003A patent/IL163550A0/xx unknown
- 2003-02-14 WO PCT/IB2003/000505 patent/WO2003068191A1/en not_active Ceased
- 2003-02-14 JP JP2003567375A patent/JP2005522444A/ja active Pending
- 2003-02-14 AP APAP/P/2004/003112A patent/AP2004003112A0/en unknown
- 2003-02-14 PL PL03371337A patent/PL371337A1/xx not_active Application Discontinuation
- 2003-02-14 EA EA200401059A patent/EA200401059A1/ru unknown
- 2003-02-14 CA CA002475722A patent/CA2475722A1/en not_active Abandoned
- 2003-02-14 EP EP03405088A patent/EP1336405A1/en not_active Withdrawn
-
2004
- 2004-08-13 IS IS7404A patent/IS7404A/is unknown
- 2004-08-13 CO CO04079402A patent/CO5600997A2/es not_active Application Discontinuation
- 2004-08-16 EC EC2004005235A patent/ECSP045235A/es unknown
- 2004-09-01 ZA ZA200406970A patent/ZA200406970B/en unknown
- 2004-09-09 NO NO20043790A patent/NO20043790L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL163550A0 (en) | 2005-12-18 |
| PL371337A1 (en) | 2005-06-13 |
| CA2475722A1 (en) | 2003-08-21 |
| EP1336405A1 (en) | 2003-08-20 |
| AR038839A1 (es) | 2005-01-26 |
| HRP20040829A2 (en) | 2006-07-31 |
| EA200401059A1 (ru) | 2005-02-24 |
| ZA200406970B (en) | 2005-06-20 |
| KR20040101229A (ko) | 2004-12-02 |
| IS7404A (is) | 2004-08-13 |
| OA12777A (en) | 2006-07-06 |
| MXPA04007905A (es) | 2004-11-26 |
| BR0307720A (pt) | 2005-01-25 |
| CO5600997A2 (es) | 2006-01-31 |
| JP2005522444A (ja) | 2005-07-28 |
| ECSP045235A (es) | 2004-09-28 |
| CN1642526A (zh) | 2005-07-20 |
| AU2003245736A1 (en) | 2003-09-04 |
| WO2003068191A1 (en) | 2003-08-21 |
| NO20043790L (no) | 2004-11-08 |
| AP2004003112A0 (en) | 2004-09-30 |
| US20030175338A1 (en) | 2003-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030935A1 (es) | Formulacion de atorvastatina estabilizada con aditamentos de metales alcalinos | |
| AR077864A1 (es) | Microgranulos flotantes | |
| NZ600441A (en) | Hair growth and / or regrowth compositions | |
| MX2021005119A (es) | Formulacion aerosolizada. | |
| NZ793239A (en) | Surfactants for electronics products | |
| MX9702456A (es) | Composicones antiacidas liquidas que contienen carbonato de calcio y posiblemente simeticona como compuestos activos y fosfato de potasio monobasico y bicarbonato de potasio como regulador. | |
| TW200518786A (en) | Solid preparation | |
| ES2547644T3 (es) | Procedimiento de molienda | |
| GB1245131A (en) | Concentrate for fire extinguishing | |
| MY207175A (en) | External preparation | |
| GB1172078A (en) | Metal Alkyl Carbonates or Thiolcarbonates and Method of Making the Same | |
| JPS53107486A (en) | Stabilized nadh aqueous solution | |
| AR039693A1 (es) | Composiciones antiacidas liquidas | |
| MXPA04001120A (es) | Sistema de blanqueo dental de multiples partes y metodos para blanquear dientes usando tales sistemas. | |
| JPS5488214A (en) | Preparation of sorbic acid crystals | |
| MY135802A (en) | Aqueous agrochemical suspension composition | |
| CR7419A (es) | Formulacion de atorvastatina estabilizada con aditamentos de metales alcalinos | |
| KR20250137638A (ko) | 포 소화제 원액 | |
| PA8499701A1 (es) | Procedimiento para preparar inhibidores de 5-lipoxigenasa que tienen sistemas variados de anillos heterocíclicos | |
| RU2000117412A (ru) | Состав для холодного фосфатирования металлических поверхностей | |
| MX2020011835A (es) | Proceso de estabilizacion de hidrosulfito. | |
| AR118884A1 (es) | Composiciones herbicidas | |
| JPS5252269A (en) | Crusher | |
| JPS52106882A (en) | Synthesis of crown ether analogues | |
| RU2013123343A (ru) | Вяжущее |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |